Humulin R Cartridge

Humulin R Cartridge is a prescription‑only insulin product that contains recombinant human insulin (Insulin human rDNA) as its active ingredient. It is supplied in a cartridge designed for use with compatible insulin pens, allowing subcutaneous administration. The cartridge provides a short‑acting insulin formulation intended for rapid onset of action after injection. It is marketed in the European Union and is classified as a short‑acting antidiabetic agent.

Humulin R Cartridge is indicated for the management of blood glucose levels in patients with diabetes who require short‑acting insulin therapy. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other glucose‑lowering agents. - Initiates rapid reduction of post‑prandial blood glucose. - Suitable for mealtime dosing in type 1 diabetes. - Used when basal insulin alone does not achieve target glycemia in type 2 diabetes. - Can be combined with long‑acting insulin analogues for basal‑bolus regimens. - Administered via insulin pen for precise dose adjustment.

Adverse reactions to Humulin R Cartridge can vary in frequency and severity; they are typically categorized as common or serious.

Common: - Mild hypoglycemia presenting as shakiness, sweating, hunger, or irritability. - Injection‑site reactions such as redness, swelling, itching, or bruising. - Lipodystrophy characterized by localized fat accumulation (lipohypertrophy) or loss (lipoatrophy) at the injection site. - Transient weight gain often observed with improved glycemic control and fluid retention.

Serious: - Severe hypoglycemia with loss of consciousness, seizures, or need for assistance from another person. - Allergic reactions ranging from urticaria and angioedema to life‑threatening anaphylaxis. - Persistent hyperglycemia or ketoacidosis suggesting inadequate insulin effect or dosing error. Most patients experience only mild symptoms, but monitoring is essential.

When using Humulin R Cartridge, several precautions should be observed to minimize risks and ensure optimal therapeutic outcomes. - Verify the cartridge is intact, not expired, and stored according to label instructions. - Rotate injection sites to reduce the risk of lipodystrophy and improve absorption. - Adjust dose based on carbohydrate intake, physical activity, and blood glucose monitoring. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Educate patients on recognizing and treating hypoglycemia promptly. - Avoid use in individuals with known hypersensitivity to recombinant human insulin or any excipients.

Humulin R Cartridge may interact with other medicines, affecting blood glucose levels or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase the risk of low blood glucose. - Corticosteroids or thiazide diuretics, which can raise glucose levels and require insulin dose changes. - Alcohol consumption, which can cause delayed hypoglycemia after insulin administration.